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Abstract
Inflammatory breast cancer (IBC) is themost insidious form of locally advanced breast cancer;
about a third of patients have distant metastasis at initial staging. Emerging evidence suggests
that host factors in the tumor microenvironment may interact with underlying IBC cells to make
them aggressive. It is unknown whether immune cells associated to the IBCmicroenviron-
ment play a role in this scenario to transiently promote epithelial to mesenchymal transition
(EMT) in these cells. We hypothesized that soluble factors secreted by activated immune cells
can induce an EMT in IBC and thus promote metastasis. In a pilot study of 16 breast cancer
patients, TNF-α production by peripheral blood T cells was correlated with the detection of circu-
lating tumor cells expressing EMTmarkers. In a variety of IBCmodel cell lines, soluble factors
from activated T cells induced expression of EMT-related genes, including FN1, VIM, TGM2,
ZEB1. Interestingly, although IBC cells exhibited increased invasion andmigration following
exposure to immune factors, the expression of E-cadherin (CDH1), a cell adhesionmolecule,
increased uniquely in IBC cell lines but not in non-IBC cell lines. A combination of TNF-α, IL-6,
and TGF-βwas able to recapitulate EMT induction in IBC, and conditioned media preloaded
with neutralizing antibodies against these factors exhibited decreased EMT. These data sug-
gest that release of cytokines by activated immune cells may contribute to the aggressiveness
of IBC and highlight these factors as potential target mediators of immune-IBC interaction.
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Introduction
Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast can-
cer, characterized by diffuse erythema and edema of the breast that is often mistaken for masti-
tis. Yet IBC is not considered a true inflammatory condition; rather inflammation that arises
from the characteristic tumor emboli that block the dermal lymphatics [1]. The tumor pro-
gresses quickly, often within a few weeks or months, and is often metastatic at diagnosis [2, 3].
This rapid onset of metastasis suggests lymphatic or hematogenous dissemination at an early
stage of disease.
Since tumor cells are in regular contact with immune cells trafficking through the lymphat-
ics, the lack of tumor control is suggestive of a compromised immune surveillance system.
However, IBC may present with an augmented cellular immune response to tumor antigen
and showed that IBC patients have normal delayed-type hypersensitivity reactions to standard
recall antigens and breast tumor lysate [4]. The effect of this postulated immune response on
tumor cells and their metastatic potential is only beginning to be explored. Recently, it was
shown that when factors secreted by the monocytic cell line U937 are added to cultures of the
IBC cell line SUM149, the tumor cells develop enhanced migratory and invasive features [5]
and increased expression of fibronectin [6]. Activated immune cells are capable of producing
factors such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and transforming
growth factor (TGF)-β that induce epithelial-to-mesenchymal transition (EMT). These charac-
teristics suggest that immune cells may induce an EMT in IBC.
EMT is a set of biological processes that occur as epithelial cells lose their sedentary charac-
teristics and gain a motile phenotype. Type I EMT [7], characteristic of cell migration during
embryogenesis is characterized by expression of genes such as SOX2, SNAI1, and SNAI2 that
encode transcription factors that control EMT. Type II EMT, involved in wound repair, tissue
regeneration, and fibrosis, is characterized by inflammation, and TGF-β signaling is frequently
involved. Neoplastic cells undergoing type III EMT hijack hallmarks of both of these programs,
producing a metastatic pathology. EMT, regardless of type, is characterized primarily by a loss
of E-cadherin (CDH1) expression mediated by the expression of transcription factors such as
SNAI1 [8], SNAI2[9], and ZEB1 [10] that bind directly to E-box regions in the E-cadherin pro-
moter and repress protein expression[11]. TWIST1 [12], mesenchyme forkhead 1 (FOXC2)
[13], and tissue transglutaminase (TGM2) [14, 15] have also been shown to regulate EMT. We
have recently demonstrated that detection of any of these EMT-related transcription factors
(EMT-TFs) or TGM2 in the peripheral blood of breast cancer patients can serve as a surrogate
for circulating tumor cells (CTC) in breast cancer patients [16]. Furthermore, the detection of
EMT factors in blood was correlated with the detection of CTC with stem-cell phenotypes
[17]. Interestingly, although acquisition of EMT characteristics appears to be a necessary step
in metastatic progression, IBC tumors are characterized by high levels of the cell adhesion mol-
ecule E-cadherin, even in metastatic sites [18, 19] leading some to postulate that E-cadherin
may promote tumor progression in this disease [20].
Although cytokines such as TNF-α, TGF-1 [21], IL-6 [22], and IL-1β are capable of induc-
ing EMT in breast cancer cells, the source of these factors has not been studied. We hypothe-
sized that activated immune cells can deliver such factor to the tumor microenvironment. In
the current study, soluble factors secreted by healthy donor peripheral blood mononuclear
cells (PBMC) were added to cultures of breast cancer cells. Through transcriptional profiling
and real-time cell analysis, we found that secreted factors from activated immune cells are
capable of inducing EMT in IBC cells. Paradoxically and unique to IBC, the induction of EMT
was concomitant with increased E-cadherin expression as characteristically seen in tumor
samples.
Immune Induced EMT in IBC Cells
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Materials and Methods
Ethics statement
The study has been approved by the Institutional Review Board (IRB) at The University of
Texas MD Anderson Cancer Center, and adhered to the tenets of the Declaration of Helsinki.
Written informed consent was obtained from each participant prior to sample collection.
EMT in circulating tumor cells from patients
Blood was collected under IRB-approved protocols LAB08-0199 and LAB08-0079 for the
detection of CTC undergoing EMT (EMT-CTC) by real-time reverse transcription-polymerase
chain reaction (RT-PCR) following depletion of CD45+ leukocytes [16]. Matched archived
PBMCs were stimulated overnight through the T-cell receptor (TCR) with immobilized anti-
CD3 and soluble anti-CD28 antibodies and stained for intracellular cytokine production of
TNF-α for analysis by flow cytometry [23, 24].
Cell lines
IBC cell lines were grown in IBC medium in 2D culture, as previously described [25, 26]. Addi-
tional breast cancer cell lines are outlined in S1 Table. All cell lines were grown at 37°C in a 5%
carbon dioxide humidified atmosphere in standard 2-D culture. SUM149 and SUM190 were
obtained from Dr. Stephen Ethier (Kramanos Institute, MI, USA) and are commercially avail-
able (Asterand, Detroit, MI). IBC-3 cells were provided courtesy of Dr. Wendy Woodward
[26]. KPL4 was provided courtesy of Dr. Junichi Kurebayashi (Kawasaki Medical School, Kura-
shiki, Japan) [27].
Preparation of activated immune cell conditioned medium
Fresh PBMCs were cultured at an initial density of 1 x 106 cells/mL in RPMI 1640 medium sup-
plemented with 10% Gibco certified FBS (Life Technologies, Grand Island, NY) plus antibi-
otic-antimycotic agents. Thereafter, the PBMCs, were stimulated either through the TCR as
above to activate T cells [28] (TCR-CM), through the Toll-like Receptor 4 (TLR4) using 10 μg/
mL lipopolysaccharide (LPS) to activate monocytes (LPS-CM), or left unstimulated (US-CM).
After 48 hours, the resulting immune-cell-conditioned media (immune cell CM) were col-
lected, centrifuged at 400g, passed through a 0.22-μm filter and stored frozen in multiple ali-
quots at -80°C. Prior to culturing with breast cancer cell lines, the CM were diluted 1:4 with the
appropriate culture medium for each cell line. TGF-β1 (R&D Systems, Minneapolis, MN) was
used at a concentration of 2 ng/mL in the appropriate media as a positive control for EMT
induction.
xCELLigence real-time growth, adhesion and migration assays
Changes in migratory and invasive capacity of SUM149 IBC cells, cell migration were quanti-
fied with an xCELLigence Real-Time Cell Analyzer using cell invasion and migration (CIM)
plates (Acea Biosciences, Inc., San Diego, CA) in serum-free media using FBS as a chemoattrac-
tant for SUM149 cells. Growth and adhesion were measured using E-plates. The xCELLigence
system detects changes in cell number, adhesion, and morphology that affect ionic impedance.
This increased electrical impedance is normalized as a “cell index.” The CIM plate is essentially
a Boyden chamber that measures increasing impedance on the lower surface of a semi-perme-
able membrane as cells migrate into the lower chamber [29]. To ensure that chemoattractant
factors in the CM did not affect migration, 25% CM were placed in both the upper and lower
chambers. The CM were diluted with serum-free IBC medium in the upper chamber, while the
Immune Induced EMT in IBC Cells
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lower chamber used IBC medium supplemented with 10% FBS. Serum-free medium in the
lower chamber served as a negative migration control. Cells were suspended in the appropriate
medium and added to the upper chamber as per the manufacturer’s protocol. Impedance was
measured on the receiving surface in the lower chamber as an indicator of cell migration and
normalized to a cell index with RTCA software version 1.2.0.0909 (Roche Applied Science,
Indianapolis, IN, under license from Acea Biosciences).
Gene expression analysis by quantitative polymerase chain reaction
Following the treatment times as noted, samples were collected in Qiazol (Qiagen, Valencia,
CA) and total RNA was extracted with the miRNeasy Mini Kit (Qiagen). cDNA was synthesized
from 1 μg of RNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies,
Foster City, CA), as previously described [25]. Gene expression was quantified with RT-PCR
using TaqMan gene expression assays (Life Technologies) listed in listed in S2 Table. Relative
expression was quantified using the ΔΔCt method using glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) as the normalizer and the cells grown in IBC medium as the reference.
Cell block and immunohistochemistry
Control cells (MCF-7 and MDA-MB-231) were grown on plastic in 2D cultures in the appro-
priate media as noted above, and SUM149 cells were exposed to CM for 48 hours. Cells were
harvested following trypsinization and washed twice in PBS. Cytospins of 5x105 cells were
stained with Diff-Quik. Additionally, 2x107 cells for each cell line were fixed in 10% formalin
for 16 hours, pelleted by centrifugation, and embedded in paraffin, as previously described [30]
to prepare cell blocks for sectioning and immunohistochemical analysis.
Fluidigm qRT-PCR array
An extended panel of EMT-related mRNAs from multiple cell lines was prepared for gene
expression using the BioMark 48.48 Dynamic Array and BioMark HD thermocycler (Fluidigm
Corporation, San Francisco, CA) [31] after 14 cycles of pre-amplification using pooled Taq-
Man gene expression assays for specific target-amplification. Samples were analyzed using
Real-Time PCR Analysis Software Version 2.0 (Fluidigm). Relative gene expression changes
were calculated with the ΔΔCT method using GAPDH as the endogenous control and cells
grown in the appropriate medium control as the normalizer for each cell line.
Cytokine measurement
Small aliquots of CM were analyzed using Millipore Milliplex kits (EMDMillipore, Billerica,
MA) according to the manufacturer’s protocol using a Luminex 100 system (Luminex, Austin,
TX), as previously described [32]. Kits used included the human cytokine chemokine panel I,
human bone panel, and TGF-β1.
Signaling
To test the ability of conditioned media to induce TNF-α and IL-6 signaling pathways, phos-
phorylation of NF-kB and STAT3 were quantified. Cells were allowed to attach to tissue culture
plastic and grow for 2 days. IBC medium was then exchanged for 25% CM. At specified time
points, cells were harvested and placed in lysis medium provided as part of the Millipore
MILLIPLEXMAP Signaling Magnetic Bead Kit—Cell Signaling Multiplex Assay (EMDMilli-
pore, Billerica, MA) according to the manufacturer’s protocol and analyzed using Luminex 100.
Immune Induced EMT in IBC Cells
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Results
Patient blood shows correlation of immune activation and circulating
tumor cells with EMT characteristics
The etiology of inflammatory breast cancer is poorly understood, but it has been postulated
that an infectious process may precipitate or enhance the disease [33, 34]. Therefore, we
hypothesized that the inflammatory environment created by activated immune cells can induce
an EMT in breast cells. Since there is lymphatic and hematogenous dissemination of tumor to
metastatic sites, isolation and interrogation of these cells in transit can give insight into the rea-
sons for this highly aggressive tumor. We first examined blood from a small cohort of IBC
patients for EMT-CTC.
We hypothesized that EMT could be induced by inflammatory processes initiated by acti-
vated immune cells. Therefore, we interrogated TCR-activated T-cells for their ability to syn-
thesize TNF-α (TNT-T) (representative gating strategy shown in S1 Fig). Matched EMT-CTC
and T-cell cytokine data were evaluable from 16 breast cancer patients, as shown in Table 1.
Six patients had>225 TNF-T cells/ μL of blood and 4 of them had detectable EMT-CTC versus
only 1 among 10 patients with<225 TNF-T cells/μL of blood” (Fisher’s exact test, p = 0.036).
Although the number of patients is small, higher numbers of TNF-T cells were associated with
a greater ability to detect EMT-CTC in breast cancer patients. These data suggest a relationship
between activated immune cells and the metastatic potential of breast cancer cells.
Immune cell media induced cell growth, migration, and invasion as
measured by live, label-free real-time cell analysis
Next, to test the ability of soluble factors secreted by activated immune cells to increase the
metastatic potential of IBC cells, we established a culture system based on SUM149 IBC cells
utilizing the CM created by activated immune cells of healthy donors. Using CM rather than
co-culture avoided cell-cell contact, mitigating any cellular cytotoxicity (Fig 1a) and further
allowed for the optimal use of media for each cell type, most specifically the use of hydroco-
done in the IBC medium that would otherwise inhibit immune responses.
The TCR-CM was added to SUM149 cells and monitored in real-time using the Acea xCEL-
Ligence real-time cell analyzer. Within 10 hours of adding TCR-CM, the xCELLigence detected
an increased cell index (Fig 1b), which is a measure of cell growth and adhesion derived from
electrical impedance (see methods). Interestingly, although SUM149 cells treated with
Table 1. T cells producing TNF-α correlate with EMT-CTC in patients. PBMCs from breast cancer
patients were stimulated overnight through the T-cell receptor with anti-CD3 and anti-CD28 antibodies and
interrogated for intracellular TNF-α synthesis by multiparameter flow cytometry. Additionally, 5 mL of blood
was depleted of CD45+ leukocytes to enrich for circulating tumor cell and interrogated for expression of EMT-
related factors. There was a significant correlation between the detection of at least 1 EMT-related factor in
the CTC-enriched fraction and presence of more than 225 CD3+ T-cells per μL of blood capable of producing
TNF-α.
TCR-activated CD3+ T
Cells that produced TNF-α
per μL blood of patient
blood
Total
<225 >225
EMT CTC no EMT 9 2 11
any EMT 1 4 5
Total 10 6 16
doi:10.1371/journal.pone.0132710.t001
Immune Induced EMT in IBC Cells
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TCR-CM for 2 days clearly show decreased cell counts relative to media control or US-CM as
assessed by manual traditional trypan blue exclusion assay (S2 Fig), the real-time analysis
showed a marked increase in the cell index measurement (CIM). In fact, in 2 days, 8x103
SUM149 cells treated with TCR-CM achieved a cell index about 2 times larger than that of
20x103 SUM149 cells that were grown in IBC medium for 5 days; IBC medium SUM149 cells
had a CIM of 2.54 after 22 hours of attachment and achieved a maximum CIM of 3.09 at 70
hours after seeding, while SUM149 cells treated with TCR-CM had a CIM of 1.20 after attach-
ment that rapidly increased to 3.1 within 14 hours of treatment, and 6.07 within 43 hours of
treatment. As the CIM by the xCELLigence is affected by cell morphology and adhesion in
addition to cell growth, these data suggest that IBC cells that were exposed to TCR-CM
increased adhesion to the either the extracellular matrix, neighboring cells, or both.
We therefore tested the ability of SUM149 cells exposed to immune cell CM to transverse
a permeable membrane under chemotaxis towards a FBS gradient using xCELLigence cell
Fig 1. Immune conditionedmedia induces migration and adhesion in IBC cells. (a) Conditioned media (CM) was collected from healthy donor
peripheral blood mononuclear cells stimulated for 48 hours with LPS (LPS-CM), through the T-cell receptor (TCR-CM) or left unstimulated (US-CM). CM were
added to established SUM149 cultures at 25% of media volume and incubated an additional 48 hours prior assaying. (b) SUM149 were grown on an
xCelligence E-plate and exposed to TCR-CM, LPS-CM and US-CM at time 0. Cell index was measured at 15-minute intervals. Robust changes are observed
at 9 hours after treatment. (c) Migration towards fetal bovine serum (FBS) is enhanced by immune CM. TCR-CM (blue line) induces rapid migration of
SUM149 cells. LPS-CM enhancement of migration (green line) is noted from 7 to ~36 hours, but is not significantly different from controls (US-CM, Media, no
FBS; red, pink and light blue) at later time points.
doi:10.1371/journal.pone.0132710.g001
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invasion and migration (CIM) plates. SUM149 cells exposed to TCR-CM showed a very
rapid increase in the cell index, suggesting an induced migratory capacity (Fig 1b). Similar
migration patterns were observed when the plates were precoated with 15% Matrigel and
when cells were pretreated with immune cell CM for 48 hours and loaded into the chambers
in equal numbers (data not shown). Combined, these data show that the changes induced in
IBC cells by soluble immune factors paradoxically increase both adhesion and migration
reminiscent of a transient EMT.
Immune Conditioned media induced EMT-like changes in IBC cells
To test the hypothesis that soluble factors secreted by activated immune cells can induce EMT
in IBC cells, CM were prepared from activated immune cells and added to established 2D cul-
tures of IBC cell lines SUM149, SUM190, IBC3 and KPL4. Cells were grown 2 days in the pres-
ence of CM prior to assaying (see Fig 1a for schema). Morphological examination under bright
field revealed that cells cultured with TCR-CM and to a lesser extent, cells cultured with
LPS-CM, exhibited a mesenchymal or stressed morphology with elongated projections consis-
tent with EMT (Fig 2a).
EMT-like changes were also observed in protein expression and localization in SUM149 fol-
lowing incubation with TCR-CM when compared to reference epithelial (MCF-7) and mesen-
chymal (MDA-MB-231) cell lines (Fig 2b). Following treatment, paraffin-embedded cell blocks
were stained by immunohistochemistry for pathological review. In a standard IBC culture
medium, SUM149 cells had an epithelial expression pattern similar to luminal MCF-7 cells.
After incubation with TCR-CM, SUM149 cells have a mesenchymal phenotype more similar
to the basal/mesenchymal MDA-MB-231[35]. Consistent with the luminal-type phenotype,
MCF-7 cells expressed high E-cadherin and keratin mix (stained with an anti-CK antibody
cocktail) but lacked expression of vimentin or cytokeratins (CK)-5/6. In contrast, MDA-MB-
231 cells stained for vimentin in more than 50% of cells, lacked E-cadherin expression, and ker-
atin mix reactivity was localized mostly in the cytoplasm (with a punctate staining suggestive
of Golgi localization), consistent with the basal/mesenchymal-type phenotype.
SUM149 cells treated with TCR-CM had increased expression of vimentin and E-cadherin.
Furthermore, we found an increase of CK-5/6 expression typical of basal-like breast cancer
cells. Finally, CK localization to both the membrane and cytoplasm decreased following
TCR-CM treatment, consistent with a loss of epithelial phenotype. Together, the increased
staining of vimentin and CK-5/6 in conjunction with the decreased pan-CK suggest that factors
secreted by activated PBMC induce cellular changes consistent with an epithelial to mesenchy-
mal transition.
A small, targeted analysis of gene expression in SUM149 cells by q-PCR showed that
TCR-CM induced at least a two-fold increased expression of fibronectin (FN1), vimentin
(VIM), N-cadherin (CDH2), TGM2, and ZEB1, and slight increase in snail (SNAI1) (Fig 2c).
Interestingly, although the increased expression of these EMT-regulating genes is typically
associated with a decreased expression of E-cadherin, SUM149 cells showed a substantial
increase in E-cadherin expression in response to TCR-CM (Fig 2b and 2c). This paradoxical
increase in E-cadherin is consistent both with the increased adhesion observed in SUM149
cells in the real-time cell analysis (Fig 1) and the unique E-cadherin expression pattern in
tumor samples from IBC patients [36] where E-cadherin in maintained even in metastatic
sites[37].
Together, these data show that after exposure to immune cell CM, SUM149 IBC cells lose
epithelial characteristics and gain mesenchymal characteristics suggesting an epithelial to mes-
enchymal transition with a unique retention of E-cadherin.
Immune Induced EMT in IBC Cells
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Fig 2. Conditionedmedia from activated healthy donor PBMC induces EMT in IBC. (a) Morphological changes visualized by bright field in IBC cell lines
consistent with stress and EMT were observed following 48-hour incubation with CM. (b) Immunohistochemical stains of paraffin cell blocks: the percentage
of positive cells is listed in each image and shown in the bar graph at right. Pancytokeratin expression is shown for both percent of cells with membrane
localization (top number) and cytoplasmic localization (bottom number). MCF-7 control cells show a characteristic epithelial phenotype with high E-cadherin,
low vimentin, low keratin 5/6 expression and strong membrane and cytoplasmic localization of cytokeratins, MDA-231 control cells are mostly mesenchymal
Immune Induced EMT in IBC Cells
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Immune cell CM induced a broad EMT profile IBC and non-IBC breast
cancer cell lines
To test immune induction of EMT in additional genetic backgrounds and against a broader
array of pathways, immune cell CM was added to a panel of breast cancer cell lines described
in S1 Table. In addition to SUM-149, three additional IBC cell lines and 5 non-IBC cell lines
were evaluated using the same pool of CM. Morphological changes imaged under bright field
are shown in S3 Fig. Cells exposed to immune cell CM were generally less dense and appeared
spindly and stressed.
A panel of 24 selected genes was analyzed for each condition using Fluidigm integrated flu-
idic circuit chips (Fig 3). Most cell lines showed increased expression of EMT-regulating genes
following treatment with immune cell CM. Changes in response to LPS-CM were generally
attenuated compared to TCR-CM, possibly due to the smaller relative number of monocytes
than T cells in PBMC. ZEB1 and TGM2 were the most frequently, and highly induced EMT-
related factors, along with inflammatory factors prostaglandin E synthase 2 (PTGES2) and IL-8
(CXCL8). Consistent with induction of EMT in epithelial cells, epithelial cell adhesion molecule
(EpCAM) expression decreased with TCR-CM treatment in every cell line except SUM149.
However, in the other IBC cell lines, although EpCAM expression was reduced, this down-reg-
ulation was attenuated compared to the non-IBC cell lines (p = 0.0197). Likewise, although the
non-IBC cell lines showed no change in E-cadherin expression at this time point, 3 of the 4
IBC cell lines (SUM149, SUM190, and IBC3, but not KPL4) showed the paradoxical increase in
E-cadherin expression noted previously (p = 0.0411). While these data confirm that immune
induction of EMT is common among a range of breast cancer subtypes, IBC cells had an
abnormal response characterized by a shift toward EMT expression concurrent with main-
tained or increased E-cadherin expression.
Profile of cytokines secreted by human activated PBMC CM
As it was previously shown that inflammatory cytokines (TNF-α, IL-6, TGF-β) could promote
EMT, we confirmed the presence of these molecules in immune cell CM. We characterized the
TCR-CM, LPS-CM, and US-CM from 5 healthy donors using Luminex multiplex bead assay.
The TCR-CM contained at least a 100-fold increase in the following factors: interferon (IFN)-
γ, IL-1α, -1β, -2, -3, -5, -6, -9, -10, -12p40, -13, -17, monocyte chemotactic protein (MCP)-3,
macrophage inflammatory protein-1 beta (MIP-1β, soluble CD40 ligand (sCD40L), soluble IL-
2 receptor alpha (sIL-2Rα), TNF-α, TNF-β and vascular endothelial growth factor (VEGF). In
the LPS CM, a 100-fold increase or greater was likewise observed in the following cytokines:
granulocyte colony stimulating factor (G-CSF), IL-1α, -β, -6, -10, -12p40, IL-1 receptor antago-
nist (IL-1RA), monocyte chemotactic protein 3 (MCP-3), MIP-1α, -1β, and VEGF (Fig 4a).
We found high levels of inflammatory cytokines that regulate EMT (i.e.: TNF-α and IL-6). Spe-
cifically, TCR-CM, had an average 101-fold increase for TNF-α; an average 347-fold increase
for IL-6 and a modest average 1.6-fold increase for TGF-β (Fig 4b). A similar pattern was
obtained from LPS-CM (Fig 4b). These results indicated that upon activation, both the lym-
phocyte and monocyte components of PBMC produce cytokines that have the potential to
induce EMT.
with low E-cadherin, high vimentin and decreased cytokeratins. Following exposure to TCR-CM, SUM149 cells show increased expression of E-cadherin,
vimentin, keratin 5/6 staining and decreased pan cytokeratin staining. (c) Expression levels of EMT-related transcription factors SNAIL, ZEB1 and TG2 were
quantified by Taq-Man qRT-PCR. TCR-CM and to a lesser extent LPS-CM, induced large increases in ZEB1 and TG2.
doi:10.1371/journal.pone.0132710.g002
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Fig 3. Analysis of multiple cell lines by Fluidigm. Breast cancer cell lines were incubated with immune CM for 48 hours and mRNA was analyzed by
qRT-PCR. Media control appears as a solid black line at 1 in the center of each plot, points falling outside the circle represent increased relative expression
and lines inside are decreased. TCR-CM anti-CD3 induced EMT-related factors to varying degrees in all cell lines. Following treatment with TCR-CM, IBC
cell lines with the exception of KPL4, had increased expression of E-cadherin.
doi:10.1371/journal.pone.0132710.g003
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Neutralizing the effects of TNF-α, TGF-β, and IL-6 reversed EMT
phenotype induced by immune conditioned media
As TNF-α, TGF-β1 and IL-6 have been shown to induce EMT in other systems, we evaluated
the individual and combinatorial effects of these three cytokines in the induction of EMT in
IBC cells. Addition of human recombinant (hr) TNF-α, (hrTNF-α, hrTGF-β, or hrIL-6 syner-
gistically induced EMT in SUM149 cultures as measured by the qPCR expression of EMT-
related factors (Fig 5a). As TNF-α and IL-6 signal through NF-κB and Stat3, respectively, we
hypothesized that incubation with TCR-CM would increase activation of these pathways. After
analysis with the Millipore MultiplexMAP bead assay, whole cell lysates of SUM149 cells
showed increased Stat3 and NF-κB phosphorylation following incubation with TCR-CM (Fig
Fig 4. Characterization of conditionedmedia from activated healthy donor PBMC.Cytokine concentrations in the CM supernatants were measured by
Luminex multiplex array in 5 representative normal donors. a) Relative expression of 46 cytokines, chemokines and growth factors; b) relative expression of
TNF-α, TGF-β and IL-6 in LPS-CM, TCR-CM relative to US-CM (solid bars).
doi:10.1371/journal.pone.0132710.g004
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5b), suggesting that this CM is capable of inducing these pathways in tumor cells. Therefore,
we hypothesized that blocking TNF-α, TGF-β, and IL-6 would mitigate the induction of EMT
by immune activation. To test this hypothesis, TCR-CM was pre-absorbed with neutralizing
antibodies to each of TNF-α, TGF-β1 and IL-6 prior to incubation with SUM149 cells in cul-
ture. Compared with TCR-CM, the pre-absorbed CM showed a reduction in the expression of
E-cadherin (CDH1), EPCAM, FN1, CDH2, SNAI2, TGM2, VIM, and ZEB1 in SUM149 IBC
cells (Fig 5c). These data suggest that TNF-α, TGF-β1 and IL-6 are partially responsible for the
immune-induced changes observed in IBC cells.
Discussion
In this study, we have shown that soluble factors secreted by activated PBMC of healthy donors
including TNF-α, IL-6 and TGF-β can induce a paradoxical co-expression of EMT signaling
and E-cadherin overexpression in IBC cells. Blocking these factors can partially prevent the
development of this EMT phenotype. This paradoxical increase in migratory behavior and con-
comitant expression of the adhesion molecule E-cadherin may account for the tight adherence
of IBC cell clusters into tumor emboli that obstruct lymphatics and lead to the “inflammatory”
symptoms of IBC. These data implicate immune cell activation in mediating aspects of the IBC
phenotype in vitro, and highlight new targets for further clinical investigation.
Fig 5. TNF-α, TGF-β and IL-6 induce EMT in SUM149. a) TNF-α, TGF-β and IL-6 were added to established SUM149 cultures and assayed for EMT-
inducing transcription factors (EMT-TF). All three cytokines act additively to induce EMT-TF. B) TCR-CM induced STAT3 and NF-κB signaling in SUM149
cells as quantified by phospho-specific antibodies using Luminex multiplex beads. C) Neutralizing antibodies against TNF-α, TGF-β and IL-6 were added to
TCR-CM prior to incubating with SUM149 cells. Compared to TCR-CM without neutralization, EMT-TF expression was reduced.
doi:10.1371/journal.pone.0132710.g005
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Induction of EMT-like features by immune cells has been shown in other systems. For
example, monocytes derived factors have been implicated in IBC models [5, 6] and macro-
phage TNF-α, IL-6, and IL-1β can induce TGF-β and EMT in MCF-7 cells [38]. Here, our LPS
stimulation recapitulates these data and that soluble factors produced by TCR-activated T-cells
are also able to induce EMT. Likewise, Soria et al. showed that TNF-α and IL-1β, expressed in
over 80% of patients with relapsed breast cancer, induce hallmarks of EMT in vitro but show
concurrent increases in both migration and adhesion [39] similar to the data presented here.
Inflammation and the immune response have long been viewed as a delicate balance that
have the ability to promote a durable tumor regression or promote tumor progression [40]. A
Th2-polarized T cell response, characterized traditionally by the cytokine IL-4 but also TNF-α
and IL-6[41], has been shown to support tumor growth [42]. In contrast, a Th1 immune
response is typically associated with tumor control. The TCR-activation used here induces
polyclonal stimulation of T cells that activates both Th1 and Th2 polarized cells with little bias
[43]. Therefore, soluble factors from multiple T-cell subsets are present in the TCR-CM. How-
ever, the apparent importance of TNF-α, IL-6, and TGF-β in EMT induction suggest that a
Th2, and not Th1 polarization, contributes to this process. This is consistent with microarray
data from the World IBC Consortium that recently showed that a Th1 gene signature was asso-
ciated with attainment of a pathological complete response in IBC patients [44] suggesting that
tipping the immune response towards Th1 and away from TH2 and the induction of EMT is
beneficial in IBC.
Twist is one of the primary transcription factors responsible for driving EMT, yet we did
not observe a consistent change in Twist expression in this study. However, Twist induces inva-
sion, in part, through upregulation of platelet-derived growth factor receptor (PDGF-R) [45,
46]. As PDGF-R expression is constitutively high in IBC [47], Twist may be dispensable for
invasive properties in IBC. Furthermore, under transient exposure to TGF-β1, Snail1 actively
represses early Twist1 expression at two days, prior to Twist induction [48], consistent with the
data shown here. Therefore, the lack of increased Twist expression in response to soluble
inflammatory factors in our data can be consistent with EMT induction.
The combination of increased invasion and increased adhesion observed with the xCELLi-
gence platform and suggested by the PCR data is perplexing but not unprecedented. The
increased cell index has also been reported in the benign prostate hyperplasia cell line BPH-1
in response to TGF-β1 [49] using the same xCELLigence platform used here. The authors
argued that although TGF-β1 has anti-proliferative effects, the induction of EMT promotes cell
spreading that increases cell index.
No immune competent in vivomodel of IBC has been published making it difficult to study
the interaction of immune and IBC tumor cells. In this study, blood samples from patients sug-
gested a correlation between TNF-α production by T-cells and the presence of EMT in CTC.
The co-culture system employed here allowed testing of directional interactions from immune
cells to tumor cells and showed that soluble factors from activated immune cells induce EMT
in tumor cells.
This immune-induced EMT had striking differences from other breast cancer models. EMT
and metastatic progression are typically associated with loss of E-cadherin; indeed, even in the
short time period in this study, the non-IBC cell lines maintain or decrease E-cadherin. In
stark contrast, IBC cell lines increased expression of E-cadherin following exposure to soluble
factors secreted by activated T cells. As such, the expression of E-cadherin in response to
inflammatory signaling may contribute to the unique presentation of IBC.
Changes in population phenotype can be attributed to either the induction of new pathways
(i.e. EMT) or the selection of pre-existing rare populations. In support of the latter, inflamma-
tory factors (such as TNF-α) induce death in the majority of cells and select for resistant stem
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cells that are characterized by EMT phenotypes [50]. Accordingly, our data confirm that the
TCR-CM greatly reduces cell counts relative to controls, although we cannot confirm if the
mechanism is due to a cytostatic effect or a combination of reduced proliferation and cell
death. However, the kinetic data from the xCELLigence platform suggest selection of resistant
cells is unlikely to account for the increase in EMT phenotype as the cell index increases far
faster than stem cells would be able to repopulate a nascent niche evacuated by dead differenti-
ated cells. Therefore, the observed increase in EMT phenotype is likely a result of EMT induc-
tion rather than selection of resistant stem-cell like cells.
The data here showed that spiking IL-6 into the media had little effect on the induction of
EMT, yet depleting IL-6 from CM drastically reduced the observed EMT at the 2-day time
point. It is possible that IL-6 plays a minor role inducing EMT but has a strong role in main-
taining the EMT-like or stem-like state [51]. The data here suggest that multiple pathways
need to be blocked to prevent EMT induction, but preventing the maintenance of this state
may offer a better target.
These results reinforce the importance of inflammation in cancer progression. Indeed, anti-
inflammatory regimens have been related to decreased risk of breast cancer in most studies
[52]. Recently, a retrospective chart review of IBC patients found that lipophilic statins, which
are taken as cholesterol-lowering agents but also have potent anti-inflammatory effects [53],
were associated with increased progression-free survival [54] but not overall survival, suggest-
ing that these anti-inflammatory drugs are ineffective once metastases have formed [55]. This
is consistent with our observations that inflammatory factors induce EMT and suggests that
inflammation can induce metastatic transformation offering a prime target for therapeutic tar-
geting. Furthermore, as induction of EMT can promote immune evasion [56], reducing these
inflammatory effects may promote better tumor control by the immune system.
In summary, we have shown that immune factors can induce phenotypic, morphological,
and functional changes in breast cancer cells that are associated with EMT. Unique to IBC
model cells, E-cadherin fails to respond to the EMT program consistent with clinical observa-
tions of maintained E-cadherin in IBC patients. It is possible that similar inflammatory condi-
tions in vivomay support both the rapid metastasis and tight tumor emboli that are
characteristic of IBC and that targeted anti-inflammatory therapy may be advantageous in this
patient population.
Supporting Information
S1 Fig. Gating strategy for TNF-α synthesis by T cells. Archived PBMC from breast cancer
patients were stimulated overnight through the T-cell receptor with plate-bound anti-CD3 and
soluble anti-CD28. The total number of CD3+CD4+ and CD3+CD4- (assumed to be CD8+) T
cells synthesizing TNF-α were enumerated by flow cytometry. The percentage was back calcu-
lated based on cell surface phenotypes obtained from fresh whole blood from the same sample
to determine the number of T cells per ml of blood capable of synthesizing TNF-α. Representa-
tive sample shown.
(PDF)
S2 Fig. Pretreatment with immune-cell conditioned media decreases cell recovery. Cells
were seeded and allowed to attach for 2 days prior to adding immune conditioned media. After
an additional 2 days of culture with immune conditioned media, cells were counted manually
using trypan blue exclusion. Cell counts are plotted and the cell viability is noted to the right of
each respective bar. Cells incubated with TCR-CM had had fewer cells than control cells
although viability was not affected.
(PDF)
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S3 Fig. Morphological changes induces in breast cancer cell lines by immune conditioned
media. Immune-cell-conditioned media were added to established cultures of 10 breast cancer
cell lines and cultured for 2 days. Bright-field images are shown. Most cell lines show a shift
towards a mesenchymal-like phenotype with increased projections and fewer, looser cell clus-
ters.
(PDF)
S4 Fig. Conditioned media from activated healthy donor PBMC induces EMT in IBC.
LPS-CM, omitted in fig 2, is shown. The morphological changes observed in LPS-CM condi-
tioned breast cancer cells are not robust, likely due to the relatively small effect LPS-CM has
due to the smaller number of cells in PBMC that respond to LPS (primarily monocytes which
typically constitute 10% of PBMC).
(PDF)
S1 Table. Breast cancer cell lines. The breast cancer type, sources, and growth media of cell
lines used are outlined.
(PDF)
S2 Table. RT-PCR TaqMan assays TaqMan gene expression assays were used for RT-PCR
as listed.
(PDF)
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